- Home
- NRIX vs BCRX Comparison
NRIX vs BCRX Comparison
Compare NRIX & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- BCRX
- Stock Information
- Founded
- NRIX 2009
- BCRX 1986
- Country
- NRIX United States
- BCRX United States
- Employees
- NRIX N/A
- BCRX N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRIX Health Care
- BCRX Health Care
- Exchange
- NRIX Nasdaq
- BCRX Nasdaq
- Market Cap
- NRIX 1.3B
- BCRX 1.6B
- IPO Year
- NRIX 2020
- BCRX 1994
- Fundamental
- Price
- NRIX $19.83
- BCRX $7.51
- Analyst Decision
- NRIX Strong Buy
- BCRX Strong Buy
- Analyst Count
- NRIX 17
- BCRX 5
- Target Price
- NRIX $30.29
- BCRX $15.60
- AVG Volume (30 Days)
- NRIX 988.4K
- BCRX 2.0M
- Earning Date
- NRIX 02-13-2025
- BCRX 11-04-2024
- Dividend Yield
- NRIX N/A
- BCRX N/A
- EPS Growth
- NRIX N/A
- BCRX N/A
- EPS
- NRIX N/A
- BCRX N/A
- Revenue
- NRIX $56,424,000.00
- BCRX $412,579,000.00
- Revenue This Year
- NRIX N/A
- BCRX $38.01
- Revenue Next Year
- NRIX $3.79
- BCRX $19.04
- P/E Ratio
- NRIX N/A
- BCRX N/A
- Revenue Growth
- NRIX N/A
- BCRX 29.92
- 52 Week Low
- NRIX $7.65
- BCRX $4.03
- 52 Week High
- NRIX $29.56
- BCRX $8.88
- Technical
- Relative Strength Index (RSI)
- NRIX 38.42
- BCRX 45.56
- Support Level
- NRIX $19.38
- BCRX $7.15
- Resistance Level
- NRIX $21.67
- BCRX $7.62
- Average True Range (ATR)
- NRIX 1.34
- BCRX 0.34
- MACD
- NRIX 0.00
- BCRX -0.02
- Stochastic Oscillator
- NRIX 12.61
- BCRX 22.86
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.